CN114929268A - 4-1bbl辅助的重组修饰的安卡拉痘苗病毒(mva)的医疗用途 - Google Patents

4-1bbl辅助的重组修饰的安卡拉痘苗病毒(mva)的医疗用途 Download PDF

Info

Publication number
CN114929268A
CN114929268A CN202080092410.7A CN202080092410A CN114929268A CN 114929268 A CN114929268 A CN 114929268A CN 202080092410 A CN202080092410 A CN 202080092410A CN 114929268 A CN114929268 A CN 114929268A
Authority
CN
China
Prior art keywords
tumor
mva
leu
pro
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080092410.7A
Other languages
English (en)
Chinese (zh)
Inventor
M·欣特贝格尔
J·梅迪纳埃切韦尔斯
M·哈比扬
于尔根·豪斯曼
M·卡拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bavarian Nordic AS
Original Assignee
Bavarian Nordic AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic AS filed Critical Bavarian Nordic AS
Publication of CN114929268A publication Critical patent/CN114929268A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080092410.7A 2019-11-20 2020-11-20 4-1bbl辅助的重组修饰的安卡拉痘苗病毒(mva)的医疗用途 Pending CN114929268A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP19210369.5 2019-11-20
EP19210369 2019-11-20
EP20191226.8 2020-08-14
EP20191226 2020-08-14
EP20193706.7 2020-08-31
EP20193706 2020-08-31
PCT/EP2020/082888 WO2021099572A1 (en) 2019-11-20 2020-11-20 Medical uses of 4-1bbl adjuvanted recombinant modified vaccinia virus ankara (mva)

Publications (1)

Publication Number Publication Date
CN114929268A true CN114929268A (zh) 2022-08-19

Family

ID=73455743

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080092410.7A Pending CN114929268A (zh) 2019-11-20 2020-11-20 4-1bbl辅助的重组修饰的安卡拉痘苗病毒(mva)的医疗用途

Country Status (11)

Country Link
US (1) US20230059344A1 (https=)
EP (1) EP4061404A1 (https=)
JP (1) JP7670705B2 (https=)
KR (1) KR20220116191A (https=)
CN (1) CN114929268A (https=)
AU (1) AU2020388973A1 (https=)
BR (1) BR112022009797A2 (https=)
CA (1) CA3159666A1 (https=)
IL (1) IL293012A (https=)
MX (1) MX2022005601A (https=)
WO (1) WO2021099572A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111050790A (zh) * 2017-08-24 2020-04-21 巴法里安诺迪克有限公司 通过静脉内施用重组mva和抗体治疗癌症的组合疗法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
FI20215508A1 (en) 2020-04-09 2021-10-10 Niemelae Erik Johan Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection
CN117004579B (zh) * 2023-06-29 2024-11-15 苏州恩立维生物科技有限公司 重组溶瘤牛痘病毒及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014037124A1 (en) * 2012-09-04 2014-03-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
CN106456747A (zh) * 2014-05-13 2017-02-22 巴法里安诺迪克有限公司 用表达肿瘤抗原的重组痘病毒和免疫检查点分子拮抗剂或激动剂治疗癌症的组合疗法
WO2017120577A1 (en) * 2016-01-08 2017-07-13 Geovax Inc. Compositions and methods for generating an immune response to a tumor associated antigen
CN109152827A (zh) * 2016-02-25 2019-01-04 纪念斯隆凯特琳癌症中心 重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途
WO2019038388A1 (en) * 2017-08-24 2019-02-28 Bavarian Nordic A/S POLYTHERAPY FOR THE TREATMENT OF CANCER BY INTRAVENOUS ADMINISTRATION OF RECOMBINANT MVA AND ANTIBODY

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969609B1 (en) * 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
UA76731C2 (uk) 2000-11-23 2006-09-15 Баваріан Нордік А/С Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації
EP2345665A3 (en) 2001-12-04 2012-02-15 Bavarian Nordic A/S Flavivirus NS1 subunit vaccine
US8691502B2 (en) * 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
MX367100B (es) * 2012-02-17 2019-08-05 The Children´S Hospital Of Philadelphia Composiciones del vector aav y metodos para su transferencia genetica a celulas, organos y tejidos.
CA2942501A1 (en) * 2014-03-17 2015-09-24 Tapimmune Inc. Nucleic acid molecule vaccine compositions and uses thereof
WO2017152042A2 (en) * 2016-03-04 2017-09-08 New York University Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity
US20190345516A1 (en) * 2018-03-12 2019-11-14 Musc Foundation For Research Development Methods for treating eye disease
CA3119503A1 (en) 2018-11-20 2020-05-28 Bavarian Nordic A/S Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014037124A1 (en) * 2012-09-04 2014-03-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
US20150202272A1 (en) * 2012-09-04 2015-07-23 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
CN106456747A (zh) * 2014-05-13 2017-02-22 巴法里安诺迪克有限公司 用表达肿瘤抗原的重组痘病毒和免疫检查点分子拮抗剂或激动剂治疗癌症的组合疗法
WO2017120577A1 (en) * 2016-01-08 2017-07-13 Geovax Inc. Compositions and methods for generating an immune response to a tumor associated antigen
CN109071592A (zh) * 2016-01-08 2018-12-21 吉奥瓦科斯公司 用于产生对肿瘤相关抗原的免疫应答的组合物和方法
CN109152827A (zh) * 2016-02-25 2019-01-04 纪念斯隆凯特琳癌症中心 重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途
WO2019038388A1 (en) * 2017-08-24 2019-02-28 Bavarian Nordic A/S POLYTHERAPY FOR THE TREATMENT OF CANCER BY INTRAVENOUS ADMINISTRATION OF RECOMBINANT MVA AND ANTIBODY

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHIE KUDO-SAITO等: "4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines", VACCINE, 5 June 2006 (2006-06-05), pages 1 - 20 *
FLORIE BERTRAND等: "Blocking Tumor Necrosis Factor a Enhances CD8 T-cell–Dependent Immunity in Experimental Melanoma", MICROENVIRONMENT AND IMMUNOLOGY, 15 July 2015 (2015-07-15), pages 2619 - 2628 *
MARÍA GONZALEZ-CAO 等: "Human endogenous retroviruses and cancer", CANCER BIOL MED., 31 December 2016 (2016-12-31), pages 483 - 488 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111050790A (zh) * 2017-08-24 2020-04-21 巴法里安诺迪克有限公司 通过静脉内施用重组mva和抗体治疗癌症的组合疗法
CN111050790B (zh) * 2017-08-24 2024-07-12 巴法里安诺迪克有限公司 通过静脉内施用重组mva和抗体治疗癌症的组合疗法

Also Published As

Publication number Publication date
MX2022005601A (es) 2022-08-15
JP2023503858A (ja) 2023-02-01
EP4061404A1 (en) 2022-09-28
CA3159666A1 (en) 2021-05-27
KR20220116191A (ko) 2022-08-22
WO2021099572A1 (en) 2021-05-27
IL293012A (en) 2022-07-01
BR112022009797A2 (pt) 2022-08-16
AU2020388973A1 (en) 2022-05-26
JP7670705B2 (ja) 2025-04-30
US20230059344A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
JP6621560B2 (ja) 前立腺関連抗原を発現させるためのベクター
AU2023203000B2 (en) Oncolytic virus therapy
US9744224B2 (en) Methods for treating cancer by administration of nucleic acids encoding FAP and cancer antigens
Nowak et al. New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents
KR102684237B1 (ko) 개인 맞춤형 백신
JP7670705B2 (ja) ４－１ｂｂｌアジュバント添加した組み換え改変ワクシニアウイルスアンカラ（ｍｖａ）の医学的使用
US12180501B2 (en) Viral vectors encoding cancer/testis antigens for use in a method of prevention or treatment of cancer
CN106794234A (zh) 用于治疗her‑2阳性癌症的联合免疫疗法和放疗
CN114786715A (zh) 痘苗病毒和使用痘苗病毒的方法
US20160166680A1 (en) Cd200 inhibitors and methods of use thereof
Scholl et al. Gene therapy applications to cancer treatment
US20220211814A1 (en) Il-36 cytokine expressing oncolytic viruses for treating cancer
Bella-Carreño et al. Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis
HK40088792A (zh) 用於癌症免疫疗法的重组痘病毒
CN116948005A (zh) 一种病毒递送的新型细胞因子及在肿瘤治疗中的应用
Yurkovetsky Genetic engineering of TNF family protein-based vaccines for antitumor immunotherapy
Lee In vivo gene therapy: using a recombinant vaccinia virus as a cytokine gene delivery system to localized murine tumors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination